A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (150 mg/1000 mg) With Respect to the Metformin XR Tablet (Locally Sourced From Canada [GLUMETZA, 2 x 500 mg]) Co-administered With Canagliflozin (1 x 100 mg + 1 x 50 mg) in Healthy Fed and Fasted Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Canagliflozin (Primary) ; Canagliflozin/metformin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 01 Dec 2016 Status changed from recruiting to completed.
- 18 Aug 2016 Status changed from not yet recruiting to recruiting.
- 04 Aug 2016 New trial record